- GlobeNewswire•5 days agoSanthera to Report 2016 Preliminary Key Financial Figures and Provide Corporate Update on January 26, 2017
Liestal, Switzerland, January 20, 2017 - Santhera Pharmaceuticals (SIX: SANN) will announce its preliminary key financial figures for 2016 and provide a corporate update on Thursday, January 26, 2017, ...
- GlobeNewswire•last monthSanthera's Raxone® designated Promising Innovative Medicine and suitable candidate for further evaluation under UK Early Access to Medicines Scheme (EAMS) for treatment in Duchenne muscular dystrophy
Liestal, Switzerland, December 23, 2016 - Santhera Pharmaceuticals (SIX: SANN) announces that it has been informed that the UK`s Medicines and Healthcare Products Regulatory Agency (MHRA) designated Raxone ...
- GlobeNewswire•3 months agoSwissmedic Accepts for Review Santhera's Marketing Authorization Application for Raxone® for the Treatment of Duchenne Muscular Dystrophy
Liestal, Switzerland, November 8, 2016 - Santhera Pharmaceuticals (SIX: SANN) announces that the Swiss Agency for Therapeutic Products (Swissmedic) has accepted for review Santhera`s Marketing Authorization ...
SANN.SW : Summary for SANTHERA N - Yahoo Finance
SANTHERA N (SANN.SW)
Swiss - Swiss Delayed Price. Currency in CHF
Add to watchlist
|Day's Range||70.25 - 71.00|
|52 Week Range||37.05 - 86.35|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|